Publications

Rahman MF, Yang Y, Le BT, Dutta A, Posyniak J, Faughnan P, Sayem MA, Aguilera NS, Mohi G. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm. Nat Commun. 2022;13(1):5347. doi: 10.1038/s41467-022-32928-3. PubMed PMID: 36100596; PMCID: PMC9470702.

Dutta A, Nath D, Yang Y, Le BT, Rahman MF, Faughnan P, Wang Z, Stuver M, He R, Tan W, Hutchison RE, Foulks JM, Warner SL, Zang C, Mohi G. Genetic ablation of PIM1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models.
Leukemia. 2022;36(3):746-759. doi: 10.1038/s41375-021-01464-2. PubMed PMID: 34741118; PMCID: PMC8891046.

Dutta A, Nath D, Yang Y, Le BT, Mohi G. CDK6 Is a Therapeutic Target in Myelofibrosis. Cancer Res. 2021;81(16):4332-4345. doi: 10.1158/0008-5472.CAN-21-0590. PubMed PMID: 34145036; PMCID: PMC8373692.

Dutta A, Yang Y, Le BT, Zhang Y, Abdel-Wahab O, Zang C, Mohi G. U2af1 is required for survival and function of hematopoietic stem/progenitor cells. Leukemia. 2021;35(8):2382-2398. doi: 10.1038/s41375-020-01116-x. PubMed PMID: 33414485; PMCID: PMC8283943.

Sano S, Wang Y, Yura Y, Sano M, Oshima K, Yang Y, Katanasaka Y, Min KD, Matsuura S, Ravid K, Mohi G, Walsh K. JAK2 (V617F) -Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure. JACC Basic Transl Sci. 209;4(6):684-697. doi: 10.1016/j.jacbts.2019.05.013. PubMed PMID: 31709318; PMCID: PMC6834960.

Dutta A, Yan D, Hutchison RE, Mohi G. STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice. Br J Haematol. 2018;180(6):911-915. doi: 10.1111/bjh.14487. PubMed PMID: 28025836; PMCID: PMC5484756.

Dutta A, Hutchison RE, Mohi G. Hmga2 promotes the development of myelofibrosis in Jak2(V617F) knockin mice by enhancing TGF-β1 and Cxcl12 pathways. Blood. 2017; 130(7):920-932. doi: 10.1182/blood-2016-12-757344. PubMed PMID: 28637665; PMCID: PMC5561898.

Jobe F, Patel B, Kuzmanovic T, Makishima H, Yang Y, Przychodzen B, Hutchison RE, Bence KK, Maciejewski JP, Mohi G. Deletion of Ptpn1 induces myeloproliferative neoplasm. Leukemia. 2017;31(5):1229-1234. doi: 10.1038/leu.2017.31. PubMed PMID: 28111468; PMCID: PMC5967380.

Yang Y, Akada H, Nath D, Hutchison RE, Mohi G. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood. 2016;127(26):3410-23. doi: 10.1182/blood-2015-11-679431. PubMed PMID: 27081096; PMCID: PMC4929929.

Gu S, Chan WW, Mohi G, Rosenbaum J, Sayad A, Lu Z, Virtanen C, Li S, Neel BG, Van Etten RA. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood. 2016;127(14):1803-13. doi: 10.1182/blood-2015-06-653006. PubMed PMID: 26773044; PMCID: PMC4825414.

Yan D, Jobe F, Hutchison RE, Mohi G. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice. Leukemia. 2015;29(10):2050-61. doi: 10.1038/leu.2015.116. PubMed PMID: 26044284; PMCID: PMC4598256.

Akada H, Akada S, Hutchison RE, Mohi G. Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice. Leukemia. 2014; 28(8):1627-35. doi: 10.1038/leu.2014.52. PubMed PMID: 24480985; PMCID: PMC4117831.

Akada H, Akada S, Hutchison RE, Sakamoto K, Wagner KU, Mohi G. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells. 2014;32(7):1878-89. doi: 10.1002/stem.1711. PubMed PMID: 24677703; PMCID: PMC4063883.

Akada H, Akada S, Hutchison RE, Mohi G. Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice. Haematologica. 2012; 97(9):1389-93. doi: 10.3324/haematol.2011.059113. PubMed PMID: 22371173; PMCID: PMC3436240.

Yan D, Hutchison RE, Mohi G. Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice. Blood. 2012;120(9):1888-98. doi: 10.1182/blood-2011-09-380808. PubMed PMID: 22837531; PMCID: PMC3433092.

Akada H, Akada S, Gajra A, Bair A, Graziano S, Hutchison RE, Mohi G. Efficacy of vorinostat in a murine model of polycythemia vera. Blood. 2012;119(16):3779-89. doi: 10.1182/blood-2011-02-336743. PubMed PMID: 22408262; PMCID: PMC3335382.

Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood. 2012;119(15):3539-49. doi: 10.1182/blood-2011-03-345215. PubMed PMID: 22144185; PMCID: PMC3325041.

Zou H, Yan D, Mohi G. Differential biological activity of disease-associated JAK2 mutants. FEBS Lett. 2011;585(7):1007-13. doi: 10.1016/j.febslet.2011.02.032. PubMed PMID: 21362419; PMCID: PMC3070755.

Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-97. doi: 10.1182/blood-2009-04-215848. PubMed PMID: 20197548; PMCID: PMC2867267.

Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood. 2009;113(18):4414-24. doi: 10.1182/blood-2008-10-182626. PubMed PMID: 19179468; PMCID: PMC2676094.

Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP, Bubley GJ. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther. 2007;6(2):195-201. doi: 10.4161/cbt.6.2.3588. PubMed PMID: 17218776.

Mohi MG, Neel BG. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev. 2007; 17(1):23-30. doi: 10.1016/j.gde.2006.12.011. Review. PubMed PMID: 17227708.

Ren SY, Bolton E, Mohi MG, Morrione A, Neel BG, Skorski T. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences. Mol Cell Biol. 2005;25(18):8001-8. doi: 10.1128/MCB.25.18.8001-8008.2005. PubMed PMID: 16135792; PMCID: PMC1234343.

Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S, Morgan K, Boulton C, Shigematsu H, Keilhack H, Akashi K, Gilliland DG, Neel BG. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 2005;7(2):179-91. doi: 10.1016/j.ccr.2005.01.010. PubMed PMID: 15710330.

Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA, Neel BG. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med. 2004;10(8):849-57. doi: 10.1038/nm1084. PubMed PMID: 15273746.

Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101(9):3130-5. doi: 10.1073/pnas.0400063101. PubMed PMID: 14976243; PMCID: PMC365755.

*Sattler M, *Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002;1(5):479-92. doi: 10.1016/s1535-6108(02)00074-0. PubMed PMID: 12124177. (*equal contribution).